Many remote Aboriginal and Torres Strait Islander communities in Australia experience unacceptable high rates of STIs such as chlamydia, gonorrhoea and trichomonas, despite efforts over many years to bring these infections under control.
A key public health strategy for control of curable STIs is the provision of accurate testing and timely treatment through primary care services.
Recent technological advances have led to the development of highly accurate point-of-care (POC) tests for STIs using the GeneXpert machine, based on nucleic acid amplification technology (NAAT).
The TTANGO (Test Treat ANd GO) research trial was carried out from 2011-2016 to determine the acceptability, performance and short term health impact of this new POC technology for the detection of chlamydia (CT) and gonorrhoea (NG) in remote communities.
TTANGO2 aims to take the next key steps towards wider implementation of STI POC testing in high prevalence areas in Australia. Through TTANGO2, STI POC testing for chlamydia and gonorrhoea on the Cepheid GeneXpert will be implemented in a network of primary health services over a 5-year period to evaluate the long-term uptake, sustainability and impact of STI POC testing in these services. POC testing should lead to better control of STIs with improved health outcomes for Aboriginal and Torres Strait Islander people, and national adoption of the POC test in similar settings.